| |
FACULTY AFFILIATIONS
Rowan T Chlebowski, MD, PhD
Professor of Medicine
UCLA School of Medicine
Chief, Medical Oncology
Harbor-UCLA Medical Center
Torrance, California
Nancy Sokolowski, RNC, OCN
Breast Health Specialist
The Smilow Family
Breast Health Center
Norwalk Hospital
Norwalk, Connecticut
Karen J Stanley, RN, MSN, AOCN, FAAN Consultant, Cancer Care Issues
President, Oncology Nursing Society
Greenwich, Connecticut |
Charles L Vogel, MD
Medical Director
Cancer Research Network Inc
Plantation, Florida
Richard Zelkowitz, MD
Chief, Section Hematology/Oncology
Wittingham Cancer Center
Medical Director
The Smilow Family
Breast Health Center
Norwalk Hospital
Norwalk, Connecticut |
CONTENT VALIDATION AND DISCLOSURES
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers
and other individuals who are in a position to control the content of CE activities. All relevant conflicts of
interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized
in this activity, and patient care recommendations. PIM is committed to providing its learners with high-quality
CE activities and related materials that promote improvements or quality in healthcare and not a specific
proprietary business interest of a commercial interest.
Dr Chlebowski — Grants/Research Support: Amgen Inc, Pfizer Inc; Consulting Fees and Other Financial/Material
Support: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Novartis Pharmaceuticals, Organon, Pfizer Inc,
Sanofi-Aventis. Ms Sokolowski — No financial interests or affiliations to disclose. Ms Stanley — No financial interests
or affiliations to disclose. Dr Vogel — Grants/Research Support: Amgen Inc, AstraZeneca Pharmaceuticals
LP, Biomira Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Pharmaceuticals Inc, Genentech
BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, TAIHO
Pharmaceutical Co Ltd; Honorarium and Speakers Bureau: Amgen Inc, AstraZeneca Pharmaceuticals LP, Biomira
Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Pharmaceuticals Inc, Genentech BioOncology,
GlaxoSmithKline, Novartis Pharmaceuticals, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. Dr Zelkowitz — Speakers Bureau: Pfizer Inc, Sanofi-Aventis.
The scientific staff and consultants for Research To Practice are involved in the development and review of
content for educational activities and report the following real or apparent conflicts of interest for themselves
(or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman,
PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD
and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP
— shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen
Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche
Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational
activities.
The following PIM clinical content reviewers, Jan Hixon, RN; Linda Graham, RN; and Trace Hutchison,
PharmD, state that they or their spouse/life partner do not have any financial relationships or relationships
to products or devices with any commercial interests related to the content of this CE activity of any amount
during the past 12 months.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are
not indicated by the Food and Drug Administration. Postgraduate Institute for Medicine (PIM), Research To
Practice, Abraxis Oncology, AstraZeneca Pharmaceuticals LP and Roche Laboratories Inc do not recommend
the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are
those of the faculty and do not necessarily represent the views of PIM, Research To Practice, Abraxis Oncology,
AstraZeneca Pharmaceuticals LP and Roche Laboratories Inc. Please refer to the official prescribing information
for each product for discussion of approved indications, contraindications and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes
and their own professional development. The information presented in this activity is not meant to serve as a
guideline for patient management. Any procedures, medications or other courses of diagnosis or treatment
discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s
conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product
information and comparison with recommendations of other authorities.
|
|
